Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)
NCT05321212 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108
Last updated 2022-04-11
Summary
This study was a French multicentric cross-sectional study retrospectively of 108 consecutive advanced NSCLC patients with a PD-L1 TPS ≥50% and without EGFR/ALK aberrations treated by pembrolizumab in first line.
Conditions
- Carcinoma, Non-Small-Cell Lung
- Immunotherapy
Sponsors & Collaborators
-
University Hospital, Brest
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-01-02
- Primary Completion
- 2019-01-02
- Completion
- 2019-03-02
Countries
- France
Study Locations
More Related Trials
-
Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France
NCT06735781 ·Status: COMPLETED
-
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
NCT03774732 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
NCT04500535 ·Status: COMPLETED
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Association Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung Cancer
NCT02551211 ·Status: TERMINATED ·Phase: NA
-
Dynamics of 18-FDG Uptake in Stage III/IV Non Small Cell Lung Cancer During First Line Pembrolizumab Treatment
NCT03832348 ·Status: COMPLETED ·Phase: NA
-
Pembrolizumab for Advanced NSCLC and PS 2-3
NCT05589818 ·Status: RECRUITING ·Phase: PHASE2
-
Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
NCT04324151 ·Status: RECRUITING
-
Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients
NCT03053856 ·Status: UNKNOWN ·Phase: PHASE2
-
Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer
NCT02733250 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)
NCT05599789 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of DURVALUMAB Maintenance in Patients With Stage III Non-Small Cell Lung Cancer
NCT06564870 ·Status: ACTIVE_NOT_RECRUITING
-
Inflammation, Cachexia and Therapeutic Response in Lung Cancer Treated With Immune Checkpoint Inhibitors: Exploratory Observational Study
NCT07004868 ·Status: RECRUITING
-
A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)
NCT04393883 ·Status: UNKNOWN ·Phase: NA
-
Efficacy of Re-challenge With Immune-Checkpoints Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients: a Retrospective Observational Study
NCT04069663 ·Status: COMPLETED
-
Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists
NCT03412058 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer
NCT03574220 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients
NCT07191171 ·Status: RECRUITING
-
Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients
NCT03351361 ·Status: COMPLETED ·Phase: PHASE3
-
Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer
NCT03217071 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT05085028 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
NCT05171777 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
NCT04234113 ·Status: TERMINATED ·Phase: PHASE1
-
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
NCT01102231 ·Status: COMPLETED ·Phase: PHASE2